Fractyl Health
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3 Van de Graaff Dr Ste 200, Burlington, ...Phone Number
(781) 902-8817Website
www.fractyl.comRevenue
<$5 MillionStock Symbol
GUTSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Fractyl Health
Fractyl Health is focused on pioneering a new approach to the treatment of T2D. Despite advances in treatment over the last 50 years, metabolic diseases in general, and T2D in particular, continue to be a principal and rapidly growing driver of morbidity and mortality in the 21st century. Fractyl Health's goal is to transform T2D treatment from chronic blood glucose management to disease-modifying therapies that target the organ-level root causes of the disease. Fractyl Health's lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) in order to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root cause of metabolic diseases.Explore more
Fractyl Health Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Fractyl Health your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Fractyl Health launches new products
Earning: See what the market has to say on Fractyl Health recently announced quarterly report
Check out if Fractyl Health is spiking on competitors!
Check if Fractyl Health has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Fractyl Health had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Fractyl Health
Funding: Get notified immidiatlly once Fractyl Health has new funding data
Fractyl Health, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Fractyl Health
Compare insights from companies similar to Fractyl Health, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$7.5M
11-50
Private
$35.9M
2013
RS
Robert SokolowskiVice President, Clinical, Quality & Regulatory Affairs
Company Profile Activity
Activity Insights
Fractyl Health is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Fractyl Health is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Fractyl Health.
Fractyl Health financials insights
Gather financial insights about Fractyl Health, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$14.3M
2015
Series C
$57M
2017
Series D
$44M
2020
Series E
$55M
2021
Series F
$100M
2024
Stock Offering
$110M
Fractyl Health Tech Stack
A closer look at the technologies used by Fractyl Health
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Project
Fractyl Health has reported 1-year randomized data from the REMAIN-1 midpoint cohort, showing that Revita patients maintained more than 80% of their prior GLP-1-induced weight loss at 1 year, compared with 46% in the sham arm, with the treatment effect sustained from month 6 through month 12 under maintained blinding in a cohort where no patient reinitiated GLP-1 therapy.
Medical Research
Project
Fractyl Health has reported no safety signals from its pilot studies of Revita, with patients experiencing only mild, rare, and transient side effects for a couple of days following the procedure, and the mucosal lining healing within weeks.
Medical Research, Clinical Operations
Project
Fractyl Health has identified that patients who lose the most weight on GLP-1 drugs demonstrate the largest effect size from Revita, an observation that has been incorporated into the pre-specified statistical analysis plan, which has been cleared with the FDA.
Medical Research, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
Fractyl Health News & Media
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS
Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data, after GUTS shares lost approximately 74.86% of their value across two trading...FRACTYL HEALTH, INC. (GUTS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Fractyl Health, Inc. Investors of Upcoming Deadline
Fractyl Health Shareholders Between January 13, 2025 and January 29, 2026 - Contact Bernstein Liebhard For More Information Regarding LawsuitSueWallSt Reminds Fractyl Health, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 20, 2026 - GUTS
Allegations focus on two public offerings in August and September 2025 that allegedly raised approximately $76.7 million in net proceeds while GUTS shares traded at prices allegedly inflated by the Company’s interim Revita data. Allegations focus on two public offerings in August and September 2025 that allegedly raised approximately $76.7 million in net proceeds while GUTS shares traded at prices allegedly inflated by the Company’s interim Revita data.Deadline Alert: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
LOS ANGELES, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 20, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) securities between January 13, 2025 and January 29, 2026 inclusive (the “Class Period”).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Fractyl Health
Sign Up For FreeTo access detailed company insights
Fractyl Health is focused on pioneering a new approach to the treatment of T2D. Despite advances in treatment over the last 50 years, metabolic diseases in general, and T2D in particular, continue to be a principal and rapidly growing driver of morbidity and mortality in the 21st century. Fractyl Health's goal is to transform T2D treatment from chr... Read More
